Plain-English translation of NCT04785937 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether non-invasive imaging techniques—specifically ultrasound and MRI scans—can accurately diagnose a serious form of fatty liver disease called steatohepatitis and liver scarring (fibrosis). Currently, the only way to definitively diagnose these conditions is through a liver biopsy, which is invasive and carries risks. Researchers want to see if these imaging scans can do the job just as well or better, without needing to insert a needle into your liver.
Fatty liver disease is becoming increasingly common worldwide, and some people develop a more serious form that can lead to cirrhosis and liver failure. With new treatments on the horizon, doctors need better, safer ways to identify which patients are at risk and need treatment. This study aims to replace invasive biopsies with simple imaging scans that are safer and easier for patients.
If you join this study, you will undergo three procedures: a liver ultrasound (including a special technique to measure liver stiffness), an MRI scan of your liver, and a liver biopsy. The biopsy is used as the gold standard to compare how well the imaging scans performed. All of these tests would typically be done as part of your standard care if your doctor suspects advanced fatty liver disease, so this study essentially evaluates how accurate the imaging is by comparing it to the biopsy results.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy